News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acasti Pharma Receives Health Canada Clearance for an Open-Label Phase II Hypertriglyceridemia Trial


10/17/2011 10:11:03 AM

LAVAL, Quebec, Oct. 17, 2011 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti) (TSX.V:APO), a subsidiary of Neptune Technologies & Bioressources Inc. (Neptune), has received another positive response from Health Canada regarding its second Clinical Trial Application (CTA), thereby allowing the initiation of an open-label phase II clinical trial with CaPre®.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES